New study tracks hidden dangers of common leukemia drug

NCT ID NCT07008027

Not yet recruiting Knowledge-focused Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 6 times

Summary

This study will follow 200 children with acute lymphoblastic leukemia or lymphoma to learn more about the short- and long-term side effects of asparaginase drugs. Researchers will track how often serious toxicities occur during standard treatment and a newer therapy called SJALL23T. The goal is to better understand and manage these side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: asparaginase drugs
What this could lead to: If successful, this study could help doctors better predict and manage side effects from asparaginase therapy, making treatment safer for children with leukemia or lymphoma.
What could go wrong: This is an observational study, not a treatment trial. It will not test a new drug or cure. The results may not apply to all patients or treatment plans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute lymphoblastic leukemia Drug-Related Side Effects and Adverse Reactions lymphoblastic lymphoma mixed phenotype acute leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG TOXICITY

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.